首页> 外文OA文献 >PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

【2h】

PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

机译：PRS17 - 预算溴化物/维尔坦甾醇62.5 / 25 MCG在西班牙治疗慢性阻塞性肺病中的使用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
L.A. Vallejo-Aparicio; A. Huerta;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. COST-EFFECTIVENESS ANALYSES OF UMECLIDINIUM BROMIDE 62.5 MCG VERSUS GLYCOPYRRONIUM 44 MCG AND UMECLIDINIUM BROMIDE 62.5 MCG VERSUS TIOTROPIUM 18 MCG IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK [J] . Shah D., Driessen M., Risebrough N., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：UMECLIDINIUMIDE 62.5 MCG与糖酮和溴化物62.5毫克与噻托吡喃啶患者的成本效果分析，英国慢性阻塞性肺病患者患者
2. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial [J] . Maleki-Yazdi M. Reza, Kaelin Thomas, Richard Nathalie, Respiratory medicine . 2014,第12期

机译：umeclidinium / vilanterol 62.5 / 25 mcg和噻托溴铵18 mcg在慢性阻塞性肺疾病中的疗效和安全性：一项为期24周的随机对照试验的结果
3. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study [J] . James F Donohue, Dennis Niewoehner, Jean Brooks, Respiratory Research . 2014,第1期

机译：慢性阻塞性肺疾病患者每日一次奥克西汀/维兰特罗125/25 mcg和奥克西汀125 mcg的安全性和耐受性：一项为期52周，随机，双盲，安慰剂对照研究的结果
4. Differential Diagnosis of Asthma and Chronic Obstructive Pulmonary Diseases using Statistical Analysis on Data of Pulmonary Function Test Report [C] . Divya Singh, Bikesh Kumar Singh, Ajoy Kumar Behera International Conference for Convergence in Technology . 2021

机译：患有肺功能试验报告数据统计分析的哮喘和慢性阻塞性肺病的鉴别诊断
5. Carrying on with living: The impact of pulmonary rehabilitation on the health behaviour of older adults with chronic obstructive pulmonary disease [D] . Price, Shirley 2010

机译：继续生活：肺康复对慢性阻塞性肺疾病老年人的健康行为的影响
6. Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective [O] . M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, 2019

机译：校正至：在慢性阻塞性肺疾病的有症状患者中溴乌梅地溴铵/维兰特罗62.5 / 25 mcg与噻托溴铵/奥洛他特5/5 mcg的成本-效果分析：西班牙国家医疗保健系统的观点
7. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial [O] . Maleki-Yazdi M. Reza, Kaelin Thomas, Richard Nathalie, 2014

机译：umeclidinium / vilanterol 62.5 / 25 mcg和噻托溴铵18 mcg在慢性阻塞性肺疾病中的疗效和安全性：一项为期24周的随机对照试验的结果

PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

著录项

引文网络

相似文献

相关主题

期刊订阅